Oral upadacitinib may be a promising treatment option for patients with atopic dermatitis-type chronic hand eczema that is ...

AbbVie ABBV delivered encouraging second-quarter 2025 results last week, sending a clear message — it is effectively managing ...

After 24 weeks of treatment, Rinvoq at two doses—15 mg and 30 mg—helped 44.6% and 54.3% of adult alopecia patients achieve 80 ...

Rinvoq’s efficacy in alopecia areata is “impressive,” according to Guggenheim analysts, who said the drug could have a ...

In July, spending on TV ads for prescription drugs reached a low not seen since this time last year. | In July, spending on ...

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus ...

Move over Humira, Skyrizi and Rinvoq are expected to beat the former megablockbuster’s peak sales by the end of this year.

AbbVie’s beat Wall Street’s estimates for its top- and bottom-lines in the second quarter, boosted by sales of Skyrizi and ...

AbbVie on Wednesday said the Phase 3 study evaluating the safety and efficacy of Rinvoq in adults and adolescents with severe alopecia areata met its primary endpoint of 80% or more scalp hair ...

AbbVie said on Thursday its tariff exposure is not expected to exceed that of rivals, and raised its 2025 profit forecast ...

It's been a challenging past three years for AbbVie ( ABBV 1.84%). The pharmaceutical leader lost U.S. patent exclusivity for its top-selling medicine, Humira, and encountered a significant clinical ...

That's because AbbVie is a solid dividend payer, with a recent dividend yield of 3.4%. It's a dividend grower, too. Its total ...